Cancer Research Meeting Calendar Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nam, S.
Right arrow Articles by Jove, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nam, S.
Right arrow Articles by Jove, R.
[Cancer Research 65, 9185-9189, October 15, 2005]
© 2005 American Association for Cancer Research

Priority Reports

Action of the Src Family Kinase Inhibitor, Dasatinib (BMS-354825), on Human Prostate Cancer Cells

Sangkil Nam1, Donghwa Kim3, Jin Q. Cheng3, Shumin Zhang1, Ji-Hyun Lee2, Ralf Buettner1, Janni Mirosevich1, Francis Y. Lee4 and Richard Jove1,3

1 Molecular Oncology and 2 Biostatistics Programs, H. Lee Moffitt Cancer Center and Research Institute, 3 Department of Pathology, University of South Florida College of Medicine, Tampa, Florida; and 4 Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey

Requests for reprints: Richard Jove, Beckman Research Institute, City of Hope National Medical Center, 1500 East Duarte Rd, Duarte, CA 91010. Phone: 626-256-4673; Fax: 626-256-8708; E-mail: rjove{at}coh.org.

Src family kinases (SFK) are currently being investigated as targets for treatment strategies in various cancers. The novel SFK/Abl inhibitor, dasatinib (BMS-354825), is a promising therapeutic agent with oral bioavailability. Dasatinib has been shown to inhibit growth of Bcr-Abl–dependent chronic myeloid leukemia xenografts in nude mice. Dasatinib also has been shown to have activity against cultured human prostate and breast cancer cells. However, the molecular mechanism by which dasatinib acts on epithelial tumor cells remains unknown. In this study, we show that dasatinib blocks the kinase activities of the SFKs, Lyn and Src, in human prostate cancer cells at low nanomolar concentrations. Moreover, focal adhesion kinase and Crk-associated substrate (p130CAS) signaling downstream of SFKs are also inhibited at similar concentrations of dasatinib. Consistent with inhibition of these signaling pathways, dasatinib suppresses cell adhesion, migration, and invasion of prostate cancer cells at low nanomolar concentrations. Therefore, dasatinib has potential as a therapeutic agent for metastatic prostate cancers harboring activated SFK and focal adhesion kinase signaling.




This article has been cited by other articles:


Home page
 BloodHome page
S. R. Bandi, C. Brandts, M. Rensinghoff, R. Grundler, L. Tickenbrock, G. Kohler, J. Duyster, W. E. Berdel, C. Muller-Tidow, H. Serve, et al.
E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease
Blood, November 5, 2009; 114(19): 4197 - 4208.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Speers, A. Tsimelzon, K. Sexton, A. M. Herrick, C. Gutierrez, A. Culhane, J. Quackenbush, S. Hilsenbeck, J. Chang, and P. Brown
Identification of Novel Kinase Targets for the Treatment of Estrogen Receptor-Negative Breast Cancer
Clin. Cancer Res., October 15, 2009; 15(20): 6327 - 6340.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Y. Chen, S. Agarwal, N. M. Shaik, C. Chen, Z. Yang, and W. F. Elmquist
P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib
J. Pharmacol. Exp. Ther., September 1, 2009; 330(3): 956 - 963.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. V. Lu, S. Zhu, A. Cvrljevic, T. T. Huang, S. Sarkaria, D. Ahkavan, J. Dang, E. B. Dinca, S. B. Plaisier, I. Oderberg, et al.
Fyn and Src Are Effectors of Oncogenic Epidermal Growth Factor Receptor Signaling in Glioblastoma Patients
Cancer Res., September 1, 2009; 69(17): 6889 - 6898.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. M. Schrage, I. H. Briaire-de Bruijn, N. F.C.C. de Miranda, J. van Oosterwijk, A. H.M. Taminiau, T. van Wezel, P. C.W. Hogendoorn, and J. V.M.G. Bovee
Kinome Profiling of Chondrosarcoma Reveals Src-Pathway Activity and Dasatinib as Option for Treatment
Cancer Res., August 1, 2009; 69(15): 6216 - 6222.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. J. Armstrong and P. G. Febbo
Using Surrogate Biomarkers to Predict Clinical Benefit in Men with Castration-Resistant Prostate Cancer: An Update and Review of the Literature
Oncologist, August 1, 2009; 14(8): 816 - 827.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. L. Wheeler, M. Iida, and E. F. Dunn
The Role of Src in Solid Tumors
Oncologist, July 1, 2009; 14(7): 667 - 678.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Kantarjian, J. Cortes, D.-W. Kim, P. Dorlhiac-Llacer, R. Pasquini, J. DiPersio, M. C. Muller, J. P. Radich, H. J. Khoury, N. Khoroshko, et al.
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up
Blood, June 18, 2009; 113(25): 6322 - 6329.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Hingorani, W. Zhang, R. Gorlick, and E. A. Kolb
Inhibition of Src Phosphorylation Alters Metastatic Potential of Osteosarcoma In vitro but not In vivo
Clin. Cancer Res., May 15, 2009; 15(10): 3416 - 3422.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. Tatarov, T. J. Mitchell, M. Seywright, H. Y. Leung, V. G. Brunton, and J. Edwards
Src Family Kinase Activity Is Up-Regulated in Hormone-Refractory Prostate Cancer
Clin. Cancer Res., May 15, 2009; 15(10): 3540 - 3549.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. A. Dumont, I. Hildebrandt, H. Su, R. Haubner, G. Reischl, J. G. Czernin, P. S. Mischel, and W. A. Weber
Noninvasive Imaging of {alpha}V{beta}3 Function as a Predictor of the Antimigratory and Antiproliferative Effects of Dasatinib
Cancer Res., April 1, 2009; 69(7): 3173 - 3179.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
S. S. Houshmandi, R. J. Emnett, M. Giovannini, and D. H. Gutmann
The Neurofibromatosis 2 Protein, Merlin, Regulates Glial Cell Growth in an ErbB2- and Src-Dependent Manner
Mol. Cell. Biol., March 15, 2009; 29(6): 1472 - 1486.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
S.-F. Wong
Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia
Journal of Oncology Pharmacy Practice, March 1, 2009; 15(1): 17 - 27.
[Abstract] [PDF]

Home page
 CarcinogenesisHome page
B. Serrels, A. Serrels, S. M. Mason, C. Baldeschi, G. H. Ashton, M Canel, L. J. Mackintosh, B. Doyle, T. P. Green, M. C. Frame, et al.
A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model
Carcinogenesis, February 1, 2009; 30(2): 249 - 257.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
V. Milano, Y. Piao, T. LaFortune, and J. de Groot
Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma
Mol. Cancer Ther., February 1, 2009; 8(2): 394 - 406.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. C. Yang, J.-h. Ok, J. E. Busby, A. D. Borowsky, H.-J. Kung, and C. P. Evans
Aberrant Activation of Androgen Receptor in a New Neuropeptide-Autocrine Model of Androgen-Insensitive Prostate Cancer
Cancer Res., January 1, 2009; 69(1): 151 - 160.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
R. Buettner, T. Mesa, A. Vultur, F. Lee, and R. Jove
Inhibition of Src Family Kinases with Dasatinib Blocks Migration and Invasion of Human Melanoma Cells
Mol. Cancer Res., November 1, 2008; 6(11): 1766 - 1774.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
A. Fabarius, M. Giehl, B. Rebacz, A. Kramer, O. Frank, C. Haferlach, P. Duesberg, R. Hehlmann, W. Seifarth, and A. Hochhaus
Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib
Haematologica, August 1, 2008; 93(8): 1145 - 1154.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H. Guan, Z. Zhou, G. E. Gallick, S.-F. Jia, J. Morales, A. K. Sood, S. J. Corey, and E. S. Kleinerman
Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma
Mol. Cancer Ther., July 1, 2008; 7(7): 1807 - 1816.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Koppikar, S.-H. Choi, A. M. Egloff, Q. Cai, S. Suzuki, M. Freilino, H. Nozawa, S. M. Thomas, W. E. Gooding, J. M. Siegfried, et al.
Combined Inhibition of c-Src and Epidermal Growth Factor Receptor Abrogates Growth and Invasion of Head and Neck Squamous Cell Carcinoma
Clin. Cancer Res., July 1, 2008; 14(13): 4284 - 4291.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Q. Hou, Y. H. Wu, H. Grabsch, Y. Zhu, S. H. Leong, K. Ganesan, D. Cross, L. K. Tan, J. Tao, V. Gopalakrishnan, et al.
Integrative Genomics Identifies RAB23 as an Invasion Mediator Gene in Diffuse-Type Gastric Cancer
Cancer Res., June 15, 2008; 68(12): 4623 - 4630.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. A. Beierle, N. A. Massoll, J. Hartwich, E. V. Kurenova, V. M. Golubovskaya, W. G. Cance, P. McGrady, and W. B. London
Focal Adhesion Kinase Expression in Human Neuroblastoma: Immunohistochemical and Real-time PCR Analyses
Clin. Cancer Res., June 1, 2008; 14(11): 3299 - 3305.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. C. Siva, M. A. Wild, R. E. Kirkland, M. J. Nolan, B. Lin, T. Maruyama, F. Yantiri-Wernimont, S. Frederickson, K. S. Bowdish, and H. Xin
Targeting CUB Domain-Containing Protein 1 with a Monoclonal Antibody Inhibits Metastasis in a Prostate Cancer Model
Cancer Res., May 15, 2008; 68(10): 3759 - 3766.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. I. Park, J. Zhang, K. A. Phillips, J. C. Araujo, A. M. Najjar, A. Y. Volgin, J. G. Gelovani, S.-J. Kim, Z. Wang, and G. E. Gallick
Targeting Src Family Kinases Inhibits Growth and Lymph Node Metastases of Prostate Cancer in an Orthotopic Nude Mouse Model
Cancer Res., May 1, 2008; 68(9): 3323 - 3333.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Vultur, R. Buettner, C. Kowolik, W. Liang, D. Smith, F. Boschelli, and R. Jove
SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells
Mol. Cancer Ther., May 1, 2008; 7(5): 1185 - 1194.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. Ramirez and J. F. DiPersio
Therapy Options in Imatinib Failures
Oncologist, April 1, 2008; 13(4): 424 - 434.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. Fizazi
The role of Src in prostate cancer
Ann. Onc., November 1, 2007; 18(11): 1765 - 1773.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. Bergeron, D. Rea, V. Levy, C. Picard, V. Meignin, J. Tamburini, H. Bruzzoni-Giovanelli, F. Calvo, A. Tazi, and P. Rousselot
Lung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia: A Case Series
Am. J. Respir. Crit. Care Med., October 15, 2007; 176(8): 814 - 818.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. M. Johnson, B. Saigal, H. Tran, and N. J. Donato
Abrogation of Signal Transducer and Activator of Transcription 3 Reactivation after Src Kinase Inhibition Results in Synergistic Antitumor Effects
Clin. Cancer Res., July 15, 2007; 13(14): 4233 - 4244.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. S. Tsao, D. He, B. Saigal, S. Liu, J. J. Lee, S. Bakkannagari, N. G. Ordonez, W. K. Hong, I. Wistuba, and F. M. Johnson
Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion
Mol. Cancer Ther., July 1, 2007; 6(7): 1962 - 1972.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
S. N. Sahu, S. Nunez, G. Bai, and A. Gupta
Interaction of Pyk2 and PTP-PEST with leupaxin in prostate cancer cells
Am J Physiol Cell Physiol, June 1, 2007; 292(6): C2288 - C2296.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Nam, A. Williams, A. Vultur, A. List, K. Bhalla, D. Smith, F. Y. Lee, and R. Jove
Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells
Mol. Cancer Ther., April 1, 2007; 6(4): 1400 - 1405.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. C. Shor, E. A. Keschman, F. Y. Lee, C. Muro-Cacho, G. D. Letson, J. C. Trent, W. J. Pledger, and R. Jove
Dasatinib Inhibits Migration and Invasion in Diverse Human Sarcoma Cell Lines and Induces Apoptosis in Bone Sarcoma Cells Dependent on Src Kinase for Survival
Cancer Res., March 15, 2007; 67(6): 2800 - 2808.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Huang, K. Reeves, X. Han, C. Fairchild, S. Platero, T. W. Wong, F. Lee, P. Shaw, and E. Clark
Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient Selection
Cancer Res., March 1, 2007; 67(5): 2226 - 2238.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Jallal, M.-L. Valentino, G. Chen, F. Boschelli, S. Ali, and S. A. Rabbani
A Src/Abl Kinase Inhibitor, SKI-606, Blocks Breast Cancer Invasion, Growth, and Metastasis In vitro and In vivo
Cancer Res., February 15, 2007; 67(4): 1580 - 1588.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Chuah, T. H. Lim, A. S. T. Lim, S. L. Tien, C. H. Lim, R. Soong, F. Lee, Y. C. Linn, Y. T. Goh, F. K. Cheah, et al.
Dasatinib Induces a Response in Malignant Thymoma
J. Clin. Oncol., December 1, 2006; 24(34): e56 - e58.
[Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S. Hiscox, L Morgan, T. Green, and R. I Nicholson
Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer
Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S53 - S59.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
J M W Gee, V E Shaw, S E Hiscox, R A McClelland, N K Rushmere, and R I Nicholson
Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications
Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S77 - S88.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Serrels, I. R.J. Macpherson, T.R. J. Evans, F. Y. Lee, E. A. Clark, O. J. Sansom, G. H. Ashton, M. C. Frame, and V. G. Brunton
Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib
Mol. Cancer Ther., December 1, 2006; 5(12): 3014 - 3022.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Fiskus, M. Pranpat, M. Balasis, P. Bali, V. Estrella, S. Kumaraswamy, R. Rao, K. Rocha, B. Herger, F. Lee, et al.
Cotreatment with Vorinostat (Suberoylanilide Hydroxamic Acid) Enhances Activity of Dasatinib (BMS-354825) against Imatinib Mesylate-Sensitive or Imatinib Mesylate-Resistant Chronic Myelogenous Leukemia Cells.
Clin. Cancer Res., October 1, 2006; 12(19): 5869 - 5878.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. Xin, M. A. Teitell, D. A. Lawson, A. Kwon, I. K. Mellinghoff, and O. N. Witte
Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor
PNAS, May 16, 2006; 103(20): 7789 - 7794.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. M. Summy and G. E. Gallick
Treatment for Advanced Tumors: Src Reclaims Center Stage
Clin. Cancer Res., March 1, 2006; 12(5): 1398 - 1401.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.